Risk estimation in rheumatoid arthritis—from bench to bedside

Journal name:
Nature Reviews Rheumatology
Volume:
10,
Pages:
171–180
Year published:
DOI:
doi:10.1038/nrrheum.2013.215
Published online

Abstract

The prognosis for patients with rheumatoid arthritis (RA) who were diagnosed in the years since 2010 is much better than for individuals who were diagnosed with the disease 20 years ago. This improvement in the long-term outcome of disease is the result of earlier initiation of therapy, disease-activity-guided modification of treatment and the availability of new, and effective, drugs. Nonetheless, current treatment strategies remain population-based, rather than individualized. Decision-making processes relevant to the provision of individualized treatment require appropriate prognostication with regard to a number of variables. Here, the methods available to evaluate the performance of predictive models are discussed. In addition, I highlight the advances in risk estimation that have been made concerning three treatment decisions relevant to the management of RA that are made daily in the clinic: when to initiate treatment with DMARDs in patients in the early stages of arthritis; the ideal intensity of initial treatment; and the likely responsiveness of the patient to a particular therapy. Apart from a model predicting the development of RA, the majority of prognostic tools derived in arthritis and RA are not accurate or not validated. Hence, personalized treatment decisions in arthritis and RA are still far from bedside.

References

  1. van Nies, J. A. et al. Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology (Oxford) 49, 22102216 (2010).
  2. Ho, L. Y., de Rooy, D. P. & van der Helm-van Mil, A. H. How to define baseline erosiveness to predict radiologic progression in rheumatoid arthritis. J. Rheumatol. 40, 16241625 (2013).
  3. Thabet, M. M., Huizinga T. W., van der Heijde, D. M. & van der Helm-van Mil, A. H. The prognostic value of baseline erosions in undifferentiated arthritis. Arthritis Res. Ther. 11, R155 (2009).
  4. Porter, D. Intensive management of early rheumatoid arthritis: the TICORA and TEAR studies. Clin. Exp. Rheumatol. 4 (Suppl. 73), 3234 (2012).
  5. de Jong, P. H. et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann. Rheum. Dis. 72, 7278 (2013).
  6. Nicholls, E. M. & Stark, A. E. Bayes' theorem. Med. J. Aust. 2, 13351339 (1971).
  7. Steyerberg, E. W. et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21, 128138 (2010).
  8. Pencina, M. J., D'Agostino, R. B. Sr, D'Agostino, R. B. Jr & Vasan, R. S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 27, 157172 (2008).
  9. Pencina, M. J., D'Agostino, R. B. Sr & Steyerberg, E. W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat. Med. 30, 1121 (2011).
  10. Vickers, A. J. & Elkin, E. B. Decision curve analysis: a novel method for evaluating prediction models. Med. Decis. Making 26, 565574 (2006).
  11. van der Helm-van Mil, A. H. et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 56, 433440 (2007).
  12. Gerlag, D. M. et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann. Rheum. Dis. 71, 638641 (2012).
  13. Krabben, A. et al. MRI of hand and foot joints of patients with anticitrullinated peptide antibody positive arthralgia without clinical arthritis. Ann. Rheum. Dis. 72, 15401544 (2013).
  14. Arnett, F. C. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315324 (1988).
  15. Karlson, E. W. et al. Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk. Ann. Rheum. Dis. 69, 10771085 (2010).
  16. van de Stadt, L. A., Witte, B. I., Bos, W. H. & van Schaardenburg, D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann. Rheum. Dis. 72, 19201926 (2013).
  17. van der Helm-van Mil, A. H. et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum. 58, 22412247 (2008).
  18. Kuriya, B., Cheng, C. K., Chen, H. M. & Bykerk, V. P. Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis. Ann. Rheum. Dis. 68, 14821485 (2009).
  19. Tamai, M. et al. A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies. Arthritis Rheum. 61, 772778 (2009).
  20. Bradna, P., Soukop, T., Bastecka, D., Hrncir, Z. & Toms, J. Prediction rule in early and very early arthritis patients [abstract]. Ann. Rheum. Dis. 68 (Suppl. 3), 547 (2009).
  21. Luchikhina E. l., Karateev, D. E. & Nasonov, E. L. The use of prediction rule to predict the development of rheumatoid arthritis in Russian patients with early undifferentiated arthritis. Presented at the 2009 European League Against Rheumatism conference.
  22. Mjaavatten, M. D. et al. Validation of a proposed prediction rule for rheumatoid arthritis in a cohort of 188 patients with undifferentiated arthritis. Ann. Rheum. Dis. 67, 14821485 (2009).
  23. van der Helm-van Mil, A. H., Toes, R. E. & Huizinga, T. W. Genetic variants in the prediction of rheumatoid arthritis. Ann. Rheum. Dis. 69, 16941696 (2010).
  24. Filer, A. et al. Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis. Ann. Rheum. Dis. 70, 500507 (2011).
  25. van der Heijde, D. M. Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin. Rheumatol. 10, 435453 (1996).
  26. Drossaers-Bakker, K. W. et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 42, 18541860 (1999).
  27. Vastesaeger, N., Xu, S., Aletaha, D., St Clair, E. W. & Smolen, J. S. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 48, 11141121 (2009).
  28. Visser, K., et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann. Rheum. Dis. 69, 13331337 (2010).
  29. Saevarsdottir, S. et al. Development of a matrix risk model to predict rapid radiographic progression in early rheumatoid arthritis. Results from a randomized trial population [abstract 2513]. Arthritis Rheum. 63 (Suppl. 10), S983 (2011).
  30. Fautrel, B, et al. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Res. Ther. 14, R249 (2012).
  31. Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 18371847 (1998).
  32. Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 30, 15941602 (2000).
  33. Lillegraven, S. et al. Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis. Arthritis Care Res. (Hoboken) 65, 526533 (2013).
  34. Durnez, A., Vanderschueren, G., Lateur, L., Westhovens, R. & Verschueren, P. Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort. Ann. Rheum. Dis. 70, 634638 (2011).
  35. Romão, V. C., Canhão, H. & Fonseca, J. E. Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Med. 11, 17 (2013).
  36. Simsek, I. Predictors of response to TNF inhibitors in rheumatoid arthritis—do we have new tools for personalized medicine? Bull. NYU Hosp. Jt Dis. 70, 187190 (2012).
  37. Visser, K., et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis. 68, 10861093 (2009).
  38. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964975 (2010).
  39. Wessels J. A. et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56, 17651775 (2007).

Download references

Author information

Affiliations

  1. Department of Rheumatology, Leiden University Medical Centre, P. O. Box 9600, 2300 RC Leiden, Netherlands.

    • Annette H. M. van der Helm-van Mil

Competing interests statement

The author declares no competing interests.

Corresponding author

Correspondence to:

Author details

  • Annette H. M. van der Helm-van Mil

    Dr Annette H. M. van der Helm obtained her Medical Degree from the University of Leiden, the Netherlands, in 1998 (cum laude). In 2005 she qualified as an Internist and in 2006 she was ratified as a Rheumatologist. She obtained her PhD in 2006 (cum laude) with the thesis 'Genetics, Autoantibodies and Clinical Features in Understanding and Predicting Rheumatoid Arthritis', also from the University of Leiden. Her current research interests include early arthritis and its disease outcome, with focus on pathogenetic factors for (rheumatoid) arthritis as well as predictive factors for the disease course.

Additional data